Leucine-rich repeat kinase 2 inhibitors: a patent review (2006 - 2011). (Q38057769)

27 August 2017

Leucine-rich repeat kinase 2 inhibitors: a patent review (2006 - 2011). (English)

1 reference

27 August 2017

4

Nathanael S Gray

1 reference

27 August 2017

Xianming Deng

1

1 reference

27 August 2017

Hwan Geun Choi

series ordinal

2

1 reference

27 August 2017

Sara J Buhrlage

series ordinal

3

1 reference

27 August 2017

language of work or name

English

0 references

publication date

6 November 2012

1 reference

Expert Opinion on Therapeutic Patents

27 August 2017

1 reference

27 August 2017

22

1 reference

27 August 2017

12

1 reference

27 August 2017

1415-1426

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.729041

27 August 2017

1 reference

Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.729041

Diagnosis and treatment of Parkinson disease: molecules to medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.729041

Parkinson's disease. First of two parts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.729041

Parkinson's disease. Second of two parts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.729041

The genetics of Parkinson's syndromes: a critical review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.729041

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.729041

Recent advances in the genetics of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.729041

LRRK2 and Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.729041

LRRK2 in Parkinson's disease: biochemical functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.729041

Zeroing in on LRRK2-linked pathogenic mechanisms in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.729041

Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.729041

Kinase activity of mutant LRRK2 mediates neuronal toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.729041

Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.729041

Leucine-rich repeat kinase 2 (LRRK2) interacts with parkin, and mutant LRRK2 induces neuronal degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.729041

Leucine-rich repeat kinase 2 mutations and Parkinson's disease: three questions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.729041

Role of LRRK2 kinase dysfunction in Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.729041

Investigation of leucine-rich repeat kinase 2 : enzymological properties and novel assays.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.729041

Substrate specificity and inhibitors of LRRK2, a protein kinase mutated in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.729041

Inhibitors of leucine-rich repeat kinase-2 protect against models of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.729041

Recent advances in the development of multi-kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.729041

A Phase I study of the angiogenesis inhibitor SU5416 (semaxanib) in solid tumours, incorporating dynamic contrast MR pharmacodynamic end points

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.729041

The protein tyrosine kinase inhibitor SU5614 inhibits VEGF-induced endothelial cell sprouting and induces growth arrest and apoptosis by inhibition of c-kit in AML cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.729041

Phase I clinical and pharmacological evaluation of the multi-tyrosine kinase inhibitor SU006668 by chronic oral dosing

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.729041

A quantitative analysis of kinase inhibitor selectivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.729041

Comprehensive analysis of kinase inhibitor selectivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.729041

An analysis of the diaminopyrimidine patent estates describing spleen tyrosine kinase inhibitors by Rigel and Portola

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.729041

BCR-ABL tyrosine kinase inhibitors for chronic myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.729041

Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC stu

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.729041

Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.729041

Chemoproteomics-based design of potent LRRK2-selective lead compounds that attenuate Parkinson's disease-related toxicity in human neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.729041

High-throughput kinase profiling as a platform for drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.729041

Characterization of a selective inhibitor of the Parkinson's disease kinase LRRK2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.729041

The selectivity of protein kinase inhibitors: a further update

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.729041

Functional interrogation of the kinome using nucleotide acyl phosphates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.729041

Inhibition of LRRK2 kinase activity leads to dephosphorylation of Ser(910)/Ser(935), disruption of 14-3-3 binding and altered cytoplasmic localization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.729041

14-3-3 binding to LRRK2 is disrupted by multiple Parkinson's disease-associated mutations and regulates cytoplasmic localization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.729041

Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.729041

Characterization of TAE684 as a potent LRRK2 kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.729041

Discovery of 3,5-Diamino-1,2,4-triazole Ureas as Potent Anaplastic Lymphoma Kinase Inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.729041

Brain Penetrant LRRK2 Inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.729041

Potent, selective and cell penetrant inhibitors of SF-1 by functional ultra-high-throughput screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.729041

Discovery of selective LRRK2 inhibitors guided by computational analysis and molecular modeling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.729041

Moving beyond rules: the development of a central nervous system multiparameter optimization (CNS MPO) approach to enable alignment of druglike properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.729041

Salicylanilides as inhibitors of the protein tyrosine kinase epidermal growth factor receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.729041

GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.729041

α-synuclein, LRRK2 and their interplay in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.729041

Kinase activity is required for the toxic effects of mutant LRRK2/dardarin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.729041

LRRK2 protein levels are determined by kinase function and are crucial for kidney and lung homeostasis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.729041

Loss of leucine-rich repeat kinase 2 causes impairment of protein degradation pathways, accumulation of alpha-synuclein, and apoptotic cell death in aged mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.729041

10.1517/13543776.2012.729041

21 January 2018

Identifiers

DOI

1 reference

27 August 2017

1 reference